tiprankstipranks
Trending News
More News >

Aclaris Therapeutics price target lowered to $9 from $15 at Scotiabank

Scotiabank analyst Louise Chen lowered the firm’s price target on Aclaris Therapeutics (ACRS) to $9 from $15 and keeps an Outperform rating on the shares. The firm is lowering its price target on the stock due to lower sales for bosakitug, the analyst tells investors. The firm, however, continues to believe pipeline advancements and commercialization, as well as potential partnerships, will drive upwards earnings revisions.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1